-
Ticagrelor Monotherapy Versus Ticagrelor With Aspirin in Patients With ST-Segment Elevation Myocardial InfarctionS-J Lee, JY Cho, TICO Investigators et al. -
Pooled Analysis of Bleeding, Major Adverse Cardiovascular Events, and All-Cause Mortality in Clinical Trials of Time-Constrained Dual-Antiplatelet Therapy After Percutaneous Coronary InterventionJD McClure, JC Ramsay , C Berry et al.
-
Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age: Analysis From the PARIS RegistryJoyce LC, Baber U, Mehran R et al.
-
Acute Coronary Syndrome, Antiplatelet Therapy, and Bleeding: A Clinical PerspectiveG Tersalvi, L Biasco, GM Cioffi et al.
-
Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journeyD Cao, R Chandiramani, M Chiarito et al.
-
Safety and efficacy of the bioabsorbable polymer everolimus-eluting stent versus durable polymer drug-eluting stents in high-risk patients undergoing PCI: TWILIGHT-SYNERGYU Baber, R Chandiramani, R Mehran et al.
-
'Ticagrelor alone vs. dual antiplatelet therapy from 1 month after drug-eluting coronary stenting among patients with STEMI': a post hoc analysis of the randomized GLOBAL LEADERS trialAS Gamal, H Hara, PW Serruys et al.
-
Benefit-risk profile of extended dual antiplatelet therapy beyond 1 year in patients with high risk of ischemic or bleeding events after PCIHY Wang, RL Gao, KF Dou et al.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
